

General Membership Meeting

Friday, December 6, 2024 10:00 AM to 3:00 PM



Mission Statement

The Florida Cancer Control and Research Advisory Council was established by the Florida Legislature in 1979, under Florida Statute 1004.435, with the purpose of advising the Legislature, Governor, and Surgeon General on ways to reduce Florida's cancer burden.

1



Florida Cancer Control & Research Advisory Council Membership

(December 2024)



Chair Clement Gwede, PhD, MPH, RN, FAAN H. Lee Moffitt Cancer Center & Research Institute



Senator Colleen Burton Senate President's Appointee



Representative Linda Chaney House Speaker's Appointee



Vice Chair Erin Kobetz, PhD, MPH Sylvester Comprehensive Cancer Center University of Miami



Autumn Citta, ARNP Governor's Appointee



Christopher Cogle, MD Senate President's Appointee



Michael Diaz, MD Association of Community Cancer Centers



Paul Hull, PhD American Cancer Society



Joseph Ladapo, MD, PhD Florida's Surgeon General



Jessica MacIntyre, DNP, MBA, APRN, AOCNP Florida Nurses Association



Merritt Martin House Speaker's Appointee



Nitesh Paryani, MD Florida Medical Association



Mitchell F. Peabody, DO Florida Osteopathic Medical Association



Alfredo Quinones-Hinojosa, MD Mayo Clinic Jacksonville



Luis Raez, MD Florida Hospital Association



Ramzi G. Salloum, PhD University of Florida Health Cancer Center

BYLAWS OF THE FLORIDA CANCER CONTROL AND RESEARCH ADVISORY COUNCIL

ARTICLE I: AUTHORITY, TITLE, AND DEFINITIONS

- 1.1 AUTHORITY: The Cancer Control and Research Act (Section. 1004.435, Florida Statutes) establishes the Florida Cancer Control and Research Advisory Council (referred to as "the Council").
- 1.2 TITLE: These bylaws may be known and cited as the bylaws of the Florida Cancer Control and Research Advisory Council.
- 1.3 EXECUTIVE DIRECTOR: Employee designated by Moffitt Cancer Center to administer the Council.

ARTICLE II: LOCATION AND STAFF

- 2.1 LOCATION: The Council office shall be located at the H. Lee Moffitt Cancer Center and Research Institute.
- 2.2 STAFF: The H. Lee Moffitt Cancer Center and Research Institute shall provide staff support and other assistance as reasonably necessary for the completion of the responsibilities of the Council. An Executive Director will be assigned to facilitate coordinated functions and assist in carry out of the duties of the Council.

ARTICLE III: MISSION AND PROCEDURES

- 3.1 MISSION: In an effort to reduce morbidity and mortality associated with cancer in Florida through prevention, early detection, and state-of-the-art therapy, the mission of the Council is:
 - a. To advise the Governor, the Legislature, and state agencies on cancer control programs, policies, priorities and initiatives,
 - b. To approve a state cancer plan, and coordinate with the Biomedical Research Advisory Council on a state cancer research plan
 - c. The Council will meet in person bi annually.
- 3.2 PROCEDURES
 - 3.2.1 Advisory Capacity: Issues may be brought to the Council by any member or other interested person by notifying the Chairperson or the Executive Director. Recommendations shall be made in writing to the Governor, Legislators, the Secretary of Health, or other appropriate individuals or agencies.

ARTICLE IV: COMPOSITION OF THE COUNCIL

4.1 COMPOSITION: Membership criteria, agencies represented, and requirements for minority representation are as specified in Section 1004.435, F.S (4)(a), Florida Statutes.

ARTICLE V: NOMINATION AND APPOINTMENT PROCESS

- 5.1 APPOINTMENT PROCESS
 - 5.1.1 New Appointments
 - 5.1.1.1 Organizations, the Governor's Office, the Speaker of the House's Office, and the Florida Senate President's Office shall provide the Executive Director the name of the member they wish to appoint.
 - 5.1.2 Reappointments
 - 5.1.2.1 At the end of a member's term, the represented organization shall notify the Executive Director if they wish to reappoint their current member or appoint a new one.

ARTICLE VI: MEMBERSHIP RULES

- 6.1 TERMS OF SERVICE: Organizations appoint members for a term of four years, and can be re-appointed for an unlimited number of terms.
- 6.2 RESIGNATION: A member wishing to resign before the end of his/her term shall submit a letter of resignation to the Executive Director. Organizations must immediately appoint a new member.
- 6.3 CONFLICT OF INTEREST: No member of the Council shall participate in any discussion or decision to recommend grants or contracts to any qualified nonprofit association or to any agency of this state or its political subdivisions with which the member is associated as a member of the governing body or as an employee or with which the member has entered into a contractual arrangement.
- 6.4 REMUNERATION: Council members will serve without pay per Section 1004.435, F.S. (4)(e).

ARTICLE VII: OFFICERS

7.1 CHAIRPERSON: A chairperson shall be selected by the majority of the Council for a term of 2 years. The chairperson shall appoint an executive committee of no fewer than three members to serve at the pleasure of the chairperson. This committee will prepare material for the council but make no final decisions.

The Chairperson, or his/her proxy, will liaison with other state councils and advisory boards as needed to fulfill the duties of the Council. The Chairperson may request participation by content experts or other state council/advisory members to fulfill the duties of the Council. These consultants will have no voting capacity and must adhere to the Council Conflict of Interest policy.

7.2 VICE CHAIRPERSON: A vice chairperson shall be selected by the majority of the Council for a term of 2 years.

ARTICLE VIII: DUTIES OF THE COUNCIL

8.1 DUTIES: The duties of the Council are outlined in F.S. 1004.435 (4)(g-m), Florida Statutes.

ARTICLE IX: MEETINGS

- 9.1 REGULAR MEETINGS: The Council shall meet at least twice a year. Notification of such meetings shall be at least thirty days prior to the meeting date, and shall be published in the Florida Administrative Weekly.
- 9.2 SPECIAL MEETINGS: Special meetings may be called by the Chairperson at his/her discretion upon the written request of four members of the Council. Notification of such meetings shall be at least fifteen days in advance of the meeting date.
- 9.3 QUORUM: Nine members shall constitute a quorum for the purpose of exercising the powers of the Council. A vote of the majority of the members present is sufficient for all actions of the Council.
- 9.4 EXECUTIVE COMMITTEE MEETINGS: The Chairperson shall appoint an executive committee of no fewer than three persons to serve at the pleasure of the chairperson. This committee will prepare material for the council but make no final decisions. Meetings of executive committee members shall be noticed 10 days prior to the meeting.

- 9.5 SUBSTITUTES: If a member cannot attend a meeting, s/he may send a substitute, who is authorized to vote. The member must notify the Executive Director in writing prior to the meeting if a substitute will be attending and who the substitute will be.
- 9.6 ABSENCES: Members shall inform the Executive Director if they are unable to attend a scheduled meeting. In the event of two consecutive absences without just cause or prior notification, even if a substitute is provided, a member may be asked by the Chairperson to submit a letter of resignation. The sponsoring organization will be notified and asked to nominate another representative.
- 9.7 RULES OF ORDER: The rules contained in the current edition of Roberts Rules of Order shall govern the Council in all cases to which they are applicable, and in which they are consistent with these bylaws and any special rules of order the Council shall adopt.

ARTICLE X: AMENDMENT OF BYLAWS

10.1 PROCEDURE: The Council may prescribe, amend, and repeal bylaws governing the manner in which the business of the Council is conducted. The bylaws can be amended by a two-thirds vote of the Council provided that the proposed amendment has been submitted in writing to all members at least fifteen days in advance of the next regular or special meeting, and that a quorum is present.

ARTICLE XI: INDEMNIFICATION OF DIRECTORS AND OFFICERS

11.1 To the fullest extent permitted by law, and to the extent not covered by insurance, the Corporation shall indemnify, hold harmless, and pay on behalf of its Directors and officers, including former Directors and officers, for any and all claims and liabilities which any such Director may incur as a result of serving or having served as a Director or officer, or by reason of any action, incident, error, or omission committed as a Director or officer. In addition, the Corporation shall reimburse such Director or officer for reasonable attorneys' and legal assistants' fees and costs incurred in connection with any such claim or liability. Notwithstanding the foregoing, the Corporation shall not indemnify any Director or officer for any expenses incurred in relation to any claim or liability arising out of that Director's or officer's own willful misconduct, bad faith, gross negligence, conscious disregard for the best interests of the Corporation, recklessness, violation of criminal law (unless the Director or officer had reasonable cause to believe that his or her conduct was lawful or had no reasonable cause to believe his or her conduct was unlawful), as a result of a final adjudication, or any transaction from which the Director or officer derived an improper personal benefit, either directly or indirectly.

General Membership Meeting Agenda Friday, December 6, 2024 10:00 AM – 3:00 PM

Meeting Registration Link (for Zoom participation):

https://moffitt.zoom.us/meeting/register/tJMqduGqqjotE9aAefGe35z-f4ec9fjGG0QD

Physical Meeting Location: Moffitt Cancer Center Stabile Research Building, Trustees Boardroom, 12902 Magnolia Drive, Tampa, 33612

10:00 AM	Log-in & Networking	All Meeting Participants
10:05 AM	Welcome, Introductions & Mission Moment	Dr. Clement Gwede & Dr. Erin Kobetz
10:15 AM	Approval of Minutes from April 26, 2024 Meeting	Dr. Clement Gwede & Council
10:20 AM	Cancer Plan Revision for 2024	Dr. Clement Gwede & Council
10:25 AM	Highlights of Florida's Cancer Burden	Dr. Clement Gwede
10:40 AM	Biomedical Research Advisory Council (BRAC) Update	Dr. Danny Armstrong (designee)
11:05 AM	Cancer Centers of Excellence Revisions	Dr. Clement Gwede & Council
11:10 AM	State Legislative Update & Discussion	Sen Burton, Rep Chaney, ACS CAN
11:35 AM	Department of Health Updates	Dr. Joseph Ladapo & DOH Team
12:00 PM	Break (Lunch provided for those in-person)	
12:15 PM	Spotlight presentation: "Updates on cervical cancer screening and management in the US: Role of HPV self- collection and triage markers"	Dr. Nicolas Wentzensen
1:15 PM	State Cancer Plan Implementation – Regional Cancer Control Collaborative Updates	Dr. Erin Kobetz, Felisha Dickey & Regional Cancer Control Collaborative Coordinators
2:00 PM	Florida Cancer Plan 2030 Planning & Discussion	Dr. Clement Gwede & Dr. Erin Kobetz
2:30 PM	CCRAB Leadership	Dr. Clement Gwede & Dr. Erin Kobetz
2:40 PM	Comments	All Meeting Participants
2:50 PM	Next CCRAB Meeting	Dr. Clement Gwede
3:00 PM	Adjourn	Dr. Clement Gwede

FLORIDA CANCER CONTROL AND RESEARCH ADVISORY COUNCIL GENERAL MEMBERSHIP MEETING Friday, April 26, 2024, 10:00 AM to 3:00 PM

Council Members in Attendance

- Senator Colleen Burton Senate President's Appointee
- Representative Linda Chaney House Speaker's Appointee
- Christopher Cogle, MD Senate President's Appointee
- Mike Diaz, MD Association of Community Cancer Centers
- Clement Gwede, PhD, MPH, RN Moffitt Cancer Center (Chair)
- Paul Hull, PhD American Cancer Society
- Erin Kobetz, PhD Sylvester Comprehensive Cancer Center University of Miami (Vice Chair)
- Joseph Ladapo, MD Florida's Surgeon General, Florida Department of Health
- Merritt Martin House Speaker's Appointee
- Mitchell Peabody, DO Florida Osteopathic Medical Association
- Luis Raez, MD Florida Hospital Association
- Ramzi Salloum, PhD University of Florida Health Cancer Center

Council Members Not in Attendance

- Jessica MacIntyre, DNP, MBA, APRN, AOCNP Florida Nurses Association
- Nitesh Paryani, MD Florida Medical Association

Others

- Tiffany Albury
- Leanne Alexander
- Ellen Anderson
- Jessica Beckstrand
- Tarik Benidir
- Robert Brooks
- Jacob Brown
- Laura Corbin
- Mackenson
 Desamours
- Felisha Dickey
- Jason Feldman
- Bonnie Gaughan-Bailey
- Marnie George

- Tracey Gregory
- Angela Hahn
- Susan Harbin
- Monique Hernandez
- Caitlin Kennedy
- Christine Kucera
- Jennifer Kue
- Heather Lake-Burger
- Paul Ledford
- David Lee
- Valerie Lee
- Gary Levin
- Peyton Lurk
- Ashley Lyerly
- Justice Mbizo

- Tiffany McCaskill
- Leah Mitchem
- Julie Newberry
- Kenneth Peach
- Vickie Perez-Marrero
- Lara Prewitt
- Towana Reddick
- Lindsey Redding
- Tammy
 Semelsberger
- Georgia Sheridan
- Pamela Sirota
- Lynn Vinson
- Lauryn Watson
- Jamie Wilson

Welcome

Dr. Clement Gwede began by welcoming members and guests, taking a moment to reaffirm the Council's mission to advise the state on ways to reduce cancer burden, and reviewing the day's agenda. Council members introduced themselves.

Approval of Minutes

Dr. Gwede presented the minutes from September 29, 2023. Merritt Martin made a motion to accept the minutes. Dr. Paul Hull seconded the motion to approve the minutes. The Council concurred with no objections.

CCRAB Bylaws: Amendment Reflecting Statute Change

Dr. Gwede reviewed the proposed amendment to CCRAB bylaws, which is needed to reflect statutory change, pending signature by the Governor, adding Mayo Clinic Jacksonville to the Council's composition. Dr. Chris Cogle motioned to approve the blylaws. Dr. Mike Diaz seconded the motion. The Council concurred with no objections.

Highlights of Florida's Cancer Burden

Dr. Gwede discussed Florida's cancer burden and focus areas of the 2020-2025 Florida Cancer Plan, including disparities in diagnoses of late-stage cancers and early detection for cancer, highlighting colorectal cancer screening. He reviewed the long-term vision of reducing cancer burden for all populations in Florida. There was discussion regarding challenges in both rural and urban areas, and infrastructure needs in communities, such as transportation and broadband access as well as adequate workforce/training. Senator Colleen Burton shared that the recently passed Live Healthy Act contains many provisions to help address some of these deficits. The Council will continue to work collaboratively highlight opportunities and identify gaps.

State Legislative Update & Discussion

Senator Burton further highlighted the Live Healthy Act, which includes a number of initiatives and opportunities to improve health and health care. Susan Harbin, American Cancer Society Cancer Action Network (ACS CAN), recapped additional highlights from the legislative session, including passage of legislation to increase access to biomarker testing, increased funding for Florida's Cancer Innovation, establishment of the Cancer Connect Collaborative in statute, and increased funding for the Mary Brogan Breast and Cervical Cancer Early Detection Program. Dr. Tarik Benidir commented on the inequities in prostate cancer treatment; access is an issue, as well as differences in coverage. There was discussion regarding the need for coverage to keep up with the science.

Biomedical Research Advisory Council (BRAC) Update

Dr. Danny Armstrong gave an update on the state's cancer research programs. Dr. Armstrong discussed status of the James and Esther King Biomedical Research Program (JEK), Bankhead Coley Cancer Research Program (BC), Live Like Bella Pediatric Cancer Research Initiative (LLB), Rare Pediatric Disease Research Initiative, and the Casey DeSantis Cancer Innovation Fund. Dr. Armstrong also shared results from the BRAC's Long-Term Impact Survey and provided an update on the Florida Cancer Centers of Excellence Program. Three applications for redesignation were submitted this cycle; peer reviews have been completed and final decisions pending. There was discussion regarding the critical role interdisciplinary and institutional collaboration has in these research efforts.

Department of Health Updates

Dr. Joseph Ladapo highlighted projects related to cancer and shared tobacco report findings, including decreases in both e-cigarette use and smoking. Felisha Dickey elaborated on program efforts in breast cancer screening and early detection, colorectal cancer screening, and comprehensive cancer control, and highlighted the Department's collaboration across cancer programs, leveraging of partnerships and utilization of data. There was discussion regarding involvement of FQHCs. Dr. Rob Brooks discussed the Cancer Connect Collaborative's commitment to closing gaps in cancer care and treatment, and provided an update on the Casey DeSantis Cancer Innovation Fund. Awardees from the first cycle, which was funded at \$20 million, have been notified. The next cycle is expected to be funded at \$60 million, pending budget approval by the Governor.

Survivorship/ Palliative Care

Dr. Paul Hull reviewed cancer care plans, including survivorship plans. Modifications in standards developed by the Commission on Cancer (CoC) are anticipated. The American Cancer Society (ACS) and other stakeholders will continue to monitor and collaborate. Dr. Hull also shared information on a newly launched national ACS cohort study, Voices of Black Women, to better understand and improve the health of Black women. Felisha Dickey shared updates on the DOH Comprehensive Cancer Control Program efforts regarding survivorship, including a funding supplement for Community Health Workers. Paul Ledford discussed the national landscape and highlighted the importance of nationally recognized definitions for palliative care given the role of national payors, such as Medicare.

State Cancer Plan Implementation – Regional Cancer Control Collaborative Updates

Dr. Erin Kobetz recapped the purpose of the community implementation grant initiative, a joint effort by the offices of community outreach and engagement at Sylvester Comprehensive Cancer Center, Moffitt Cancer Center, and UF Health Cancer Center, which provides up to \$16,500 to work on projects that reflect local need and evidence-based work. Felisha Dickey introduced the Regional Cancer Control Collaborative Coordinators to provide updates on the projects they are working on through this funding mechanism as well as funding through the DOH and Tobacco Free Florida. Coordinators from each of the six regions presented on the work their Collaboratives are doing.

Florida Cancer Data System (FCDS) Update

Dr. David Lee, Gary Levin and Dr. Monique Hernandez provided an update on Florida's State Cancer Data Workgroups, which were developed to address objectives in the 2020-2025 Florida Cancer Plan. This includes an objective to form a state cancer data workgroup consisting of key stakeholders to develop strategies for adding cancer biology data, social determinants of health data, cancer screening data, and precancerous cervical pathology test results (CIN2/3, CIS) to the state cancer registry (Objective 2.1), and four sub-groups developed to focus on Cancer Plan Objectives 2.2 (focus on adding cancer biology data to the registry), 2.3 (focus on adding social determinants of health and additional patient demographic data to the registry), 2.4 (focus on the addition of cancer screening items to the registry) and 2.6 (focus on increasing access and utilization of registry data). The sub-groups have developed pilots and/or implementation strategies for each of the four objectives and have identified the resource needs and timelines to move forward. Much work is on hold as the groups try to identify funding sources for the pilot projects. There was discussion regarding the relevance and importance of enhancing the state cancer registry and need for resources as well as continued partnership as stakeholders begin to work on the 2026-2030 Florida Cancer Plan.

State and National Cancer Policy Efforts

Dr. Chris Cogle provided an update on AHCA's colorectal cancer screening and prevention initiative. Dr. Cogle also shared information on the National Cancer Policy Forum (NCPF), a collaborative effort through the National Academies. The NCPF's work entails a workshop process by which stakeholders identify a specific topic, hold proceedings, and make findings available to the public. There was discussion regarding the awareness of these resources as well as potential for Florida stakeholders to apply a similar model, which would require a source of funding.

Florida Cancer Plan 2030 Planning and Discussion

There was discussion regarding potential updates to the USPSTF guidelines for breast cancer screening, which are expected to be released this year. This type of change would meet the criteria for consideration by Council to update the 2020-2025 Florida Cancer Plan. If new recommendations are adopted by the USPSTF, the information will be shared with CCRAB members in accordance with the Council-approved plan for revising the Cancer Plan. The Council will continue to follow evolving science and ensure that current recommendations are captured in the reports the Council is statutorily required to develop and update.

Dr. Gwede discussed planning for the 2026-2030 Florida Cancer Plan and shared a general draft timeline. Stakeholder input from across the state, including through regional town hall meetings, was a critical part of the process for developing the current Plan.

Comments

Dr. Gwede invited any meeting attendees to make comments.

Next CCRAB Meeting

Dr. Gwede stated that the next CCRAB meeting will be in the Fall of 2024. Dr. Bobbie McKee will followup with Council members with additional information.

Adjourn

Dr. Gwede thanked everyone for participating. The meeting adjourned at 2:37 PM on April 26, 2024.

2020-2025 Florida Cancer Plan Proposed Revision for 2024

The Florida Cancer Control and Research Advisory Council (CCRAB) is considering a revision to the Florida Cancer Plan. The proposed revision would update screening guidelines included in one Cancer Plan Goal to reflect recent changes made by the USPSTF.

The 30-day consideration period for CCRAB Council Members to provide comments began on Monday, November 4, 2024. The Council will take up approval of the proposed revisions during the CCRAB meeting on Friday, December 6, 2024.

Breast Cancer Screening Goal/Objective:

Proposed revision changes age range to match <u>U.S. Preventive Services Task Force</u> (<u>USPSTF</u>) recommendation update.

Objective 11.2: By 2025, increase the percentage of Florida women aged 50 40 to 74 years old in every Florida community who undergo mammogram.

Additional Information:

<u>Plan for Making Changes to the Florida Cancer Plan</u> <u>Florida Cancer Plan Goals, Objectives and Strategies Selection Criteria</u> <u>https://www.ccrab.org/cancer-plan-annual-revisions</u>

Nicolas Wentzensen M.D., Ph.D., M.S.



Dr. Wentzensen is a Senior Investigator in the Division of Cancer Epidemiology and Genetics (DCEG), at the National Cancer Institute. He is Head of the Clinical Epidemiology Unit and Deputy Director of the Clinical Genetics Branch in DCEG. He earned his MD and a PhD in Applied Tumor Biology from the University of Heidelberg and a Master of Epidemiology from the University of Mainz before joining the National Cancer Institute in 2007. Dr. Wentzensen is conducting molecular epidemiology studies to understand the etiology of gynecological cancers and to develop new prevention methods. He is Co-PI of the NCI Moonshot Project to Accelerate Cervical Cancer Control.


Dr. Wentzensen has worked on HPV-associated cancers for over 20 years and has focused on cervical disease detection and the development of biomarkers for cervical cancer screening from basic research to translation in clinical and epidemiological studies. He is leading several studies to clinically validate novel biomarkers for triage of HPV-positive women and he has established studies to analyze the accuracy of cervical colposcopy and biopsy in women with abnormal screening results. Furthermore, he is the lead investigator of the IRIS Cohort, a large cervical cancer screening cohort conducted at NCI in collaboration with Kaiser Permanente Northern California.

Dr. Wentzensen has published over 600 articles and book chapters. He regularly serves as an expert on national and international committees focused on gynecological and other cancers, including the Institute of Medicine, IANS, the ACS, ASCCP, and ASCP Screening Guidelines for the Prevention and Early Detection of Cervical Cancer, and the ASCCP Management Guidelines of Women with Abnormal Cervical Cancer Screening Tests and Cancer Precursors. He is now chairing the Enduring Cervical Cancer Screening and Management Guidelines effort to regularly update cervical cancer screening and management guidelines. He co-chaired the recent update of the IARC cervical cancer screening handbook, and he plays a major role in the development of the WHO cervical cancer screening guidelines.

Nicolas Wentzensen M.D., Ph.D., M.S. Senior Investigator Head, Clinical Epidemiology Unit Deputy Director, Clinical Genetics Branch Division of Cancer Epidemiology and Genetics National Cancer Institute 9609 Medical Center Drive, Room 7-E114 Bethesda, MD 20892-9774 Phone: (240) 276-7303 Fax: (240) 276-7838 wentzenn@mail.nih.gov


CCRAB Annual Report 2024

Link to download the 2024 Annual Report: <u>https://www.ccrab.org/annual-reports</u>




Florida Cancer Plan 2020-2025

Link to download the Cancer Plan: <u>http://www.ccrab.org/cancer-plan</u>



Florida Regional Cancer Control Collaboratives:

Reducing the Cancer Burden through Collaboration



Updated October 2023